Q-omics provides the consensus-scored GAPDHP36 profile across patient tissues and cancer cell-line models. GAPDHP36 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, GAPDHP36 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, GAPDHP36 RNA expression shows 5,160 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, COAD, and STAD as cancer lineages where GAPDHP36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP36 survival associations across molecular data types. GAPDHP36 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP36 RNA expression–survival associations across cancer types. High GAPDHP36 expression shows unfavorable associations in STAD, PAAD, COAD, HNSC and KIRP, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify LUAD as the clearest survival context for GAPDHP36 RNA expression.
This table summarizes GAPDHP36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP36 shows higher tumor expression in COAD and LUSC. The COAD box plot shows higher GAPDHP36 RNA expression in tumor versus normal tissue (log2 FC = +0.048, t-test p = .037).
This table shows molecular features associated with GAPDHP36 in patient tissues and cancer cell lines. In patient samples, GAPDHP36 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
